U.S. drugmaker Moderna announced that its new coronary vaccine, mRNA-1273, was a phased success, with 45 subjects producing new coronary antibodies in the body, with the first eight producing neutralizing antibodies. This happy result helped the company’s share price jump 20%! Remember the so-called “saviour” Redsey? Now U.S. drugmaker Moderna has announced a major success in clinical trials of the new corona vaccine, in which 45 subjects were tested for the vaccine’s mRNA-1273 vaccine.
On Monday, Moderna announced the success of the human trial of the new crown vaccine, and its shares jumped 20 percent as of 7:59 a.m. Beijing time on May 19. The news also spurred a surge in U.S. stocks as a whole, extending its gains by more than 900 points in midday trading, the biggest gain in nearly a month.
As Moderna’s share price soared, Bob Langer, a 71-year-old MIT professor and one of the company’s early investors, rose to $1 billion. He owns 3.2 per cent of the company.
Dr. Langer was named one of the world’s 25 most important scientists in biotechnology by Forbes magazine as early as 1999.
He has more than 1,260 published and pending patents worldwide that have been licensed or distributed to more than 300 pharmaceutical, chemical, biotechnology and medical device companies.
45 subjects produced antibodies in the first phase and neutralizing antibodies in 8
On Monday, Moderna said the first phase of vaccination sat out healthy volunteers between the ages of 18 and 55, male and unpregnant women.
A total of 45 participants, in a group of 15 people, were vaccinated at 25 micrograms, 100 micrograms or 250 micrograms, respectively.
In the first test, each person was vaccinated twice, about four weeks apart.
The results showed that all 45 subjects produced antibodies, the first 8 were neutralizing antibodies (neutralizing antibodies), the smallest dose (25 micrograms) group on the 43rd day of the trial (two weeks after the second dose of the vaccine) in the body antibody level sympathise, while the 100 microgram group “significantly exceeded this level”, and there were no serious adverse reactions in the test.
The immune system produces neutralizing antibodies that are more resilient to the virus, can effectively prevent virus replication, and is a powerful weapon to protect the body!
This is a key advance in the development of an effective vaccine.
Moderna had previously been vaccinated in mice and then infected, and the vaccine was found to prevent the virus from replicating in the lungs of mice, which had neutral antibodies levels comparable to those in the vaccinated.
At the heart of the Moderna vaccine is mRNA , a genetic code that tells cells what antigens they should build to react to viruses.
The company said it was speeding up the process and that the second phase of testing would begin soon, with 600 participants expected to begin in July, with thousands of healthy people involved. The U.S. Food and Drug Administration (FDA) approved Moderna’s entry into the second phase of the test earlier this month.
Although the results of the experiment are encouraging, it is not known whether it will be saved.
If the trials go well, the vaccine could be widely used by the end of this year or early 2021, Dr. Tal Zaks, Moderna’s chief medical officer, said in an interview.
The first phase of Modern’s tests for the other two age groups is still being registered, including groups 55 to 70 years old and groups over 71 years old. At present, the test does not involve children. Experts say tests for children can only be carried out if the vaccine is sufficiently proven to be safe in adults.
Actual data for the preliminary tests have not been released, but have been submitted to the FDA. Moderna said it expects the data to be made public this summer.
Only the maximum dose of three participants had side effects such as fever
The main purpose of early clinical trials is to see if the vaccine is safe and whether it causes adverse reactions in a small number of people.
The researchers tested three doses of the vaccine: low, medium and high. In the low to medium dose results, the only adverse reaction was that a patient’s arm became red and sore after vaccination.
When the 250 micrograms were tested, three participants developed flu-like symptoms such as fever, muscle pain, and headache, which Dr. Zaks said would disappear after a day.
In summary, using low doses seems to work better. Modern expects the third phase of the test to focus on the situation at doses between 25 and 100 micrograms.
Vaccines Save the World, 8 New Crown Vaccines Enter Clinical Trials: Start Available as Soon as September
Dr. Fauci, a leading American immunologist, predicted that it would take 12 to 18 months to produce a new coronavaccine. But now the process has accelerated significantly!
At a glance in the Development process of Moderna
From the development process, moderna has finalized the genetic sequence of mRNA-1273 starting in January 2020. On March 16, the first volunteer completed the vaccination, which took only 63 days to complete, from the mRNA sequence of the vaccine to the first vaccination!
On April 16th it received a $483 million grant from the U.S. government’s BARDA (The Advanced Research and Development Agency) for vaccine research and development.
Moderna is one of eight companies in the world that are developing new crown vaccines for human clinical trials.
Two other U.S. companies include Pfizer and Inovio, as well as one at Oxford University in the United Kingdom and four in China.
So how are the progress of new crown vaccine development in the rest of the country?
The World Health Organization’s official website published a sketch of the COVID-19 vaccine candidate on May 15th, which lists eight new coronavirus vaccines that are in clinical trials worldwide.
At present, the vast majority of vaccines in the international community are in the preclinical research stage.
Of the eight vaccines that entered the clinical trial phase, China accounted for four, mainly adenovirus vector vaccines developed by Chen Wei’s team, and three inactivated vaccines.
The vaccine developed by Chen Wei’s team completed a phase 1 clinical trial at the end of March and launched the second phase of the clinical trial on April 12. This is the world’s first new coronary vaccine to launch phase II clinical studies.
On April 24, the inactivated vaccine developed by Wuhan Institute of Biological Products officially entered phase II clinical research. China is also the first country in the world to enter Phase II clinicalinated vaccine research.
The adenovirus vector vaccine at the Jenner Institute at Oxford University has previously demonstrated its safety in similar vaccine trials, with 1,100 people vaccinated in phase 1 clinical trials and 5,000 people participating in the second and third phases of joint trials, which will begin in May.
Pfizer and BioNTech in the U.S. announced that their mRNA vaccine will begin human testing on May 4 and, if successful, could be put into emergency use as early as September.
On April 6, Inovio launched a clinical trial of the first phase of the DNA vector vaccine. The DNA vaccine (INO-4700) used in this trial maintained a long-lasting antibody response in the subjects. The company said it plans to move forward with the second phase of the study as soon as it has initial safety and immunogenicity data for the first phase of the study.
The most optimistic message for all now is that the vaccine will be put into emergency use as soon as September.